[
  {
    "ts": null,
    "headline": "Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More",
    "summary": "Big pharma Q4 2025 beats: Lilly leads obesity/diabetes, Novo faces 2026 pressure, LOE transitions in focus.",
    "url": "https://finnhub.io/api/news?id=f8944b09b7fd83e5420be2f4af05b504c53449ae617b3594f5665404d55c833d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770453000,
      "headline": "Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More",
      "id": 138384854,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154390775/image_2154390775.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Big pharma Q4 2025 beats: Lilly leads obesity/diabetes, Novo faces 2026 pressure, LOE transitions in focus.",
      "url": "https://finnhub.io/api/news?id=f8944b09b7fd83e5420be2f4af05b504c53449ae617b3594f5665404d55c833d"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Says Stocks Like Johnson & Johnson “Simply Refuse to Quit”",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer commented on. Cramer showed an optimistic sentiment toward the stock, as he commented: Lilly’s not alone. The irrepressible Johnson & Johnson, along with the effervescent Merck and Amgen, they simply refuse to quit. Why not? Even after the runs they’ve had this year alone, […]",
    "url": "https://finnhub.io/api/news?id=8a132567ee36620bfa4c1552aeef99b5fd0b08adab66ab869ce82953710c7f8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770443802,
      "headline": "Jim Cramer Says Stocks Like Johnson & Johnson “Simply Refuse to Quit”",
      "id": 138383220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer commented on. Cramer showed an optimistic sentiment toward the stock, as he commented: Lilly’s not alone. The irrepressible Johnson & Johnson, along with the effervescent Merck and Amgen, they simply refuse to quit. Why not? Even after the runs they’ve had this year alone, […]",
      "url": "https://finnhub.io/api/news?id=8a132567ee36620bfa4c1552aeef99b5fd0b08adab66ab869ce82953710c7f8b"
    }
  },
  {
    "ts": null,
    "headline": "Review & Preview: 50,000 Sighs of Relief",
    "summary": "After a tumultuous week, stocks staged an impressive rebound, sending the Dow above 50,000 for the first time ever.",
    "url": "https://finnhub.io/api/news?id=a4ddbf1eb734759f710132871b803a21b63a2898c567ba0f499c96b93b59c044",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770425700,
      "headline": "Review & Preview: 50,000 Sighs of Relief",
      "id": 138381723,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "After a tumultuous week, stocks staged an impressive rebound, sending the Dow above 50,000 for the first time ever.",
      "url": "https://finnhub.io/api/news?id=a4ddbf1eb734759f710132871b803a21b63a2898c567ba0f499c96b93b59c044"
    }
  }
]